Stevens-Johnson Syndrome Induced by Doxycycline

Natalie N. Cac, BSE; Michael J. Messingham, MD; Patrick J. Sniezek, MD; Hobart W. Walling, MD, PhD

Stevens-Johnson syndrome (SJS) is an acute mucocutaneous eruption nosologically related to erythema multiforme (EM) and toxic epidermal necrolysis (TEN). Medications are the most common triggering factors for SJS, with anticonvulsants, sulfonamides, penicillins, allopurinol, and nonsteroidal anti-inflammatory drugs (NSAIDs) most commonly implicated. SJS is very rarely associated with tetracyclines. We report a case of doxycycline-induced SJS in a 46-year-old man.


S tevens-Johnson syndrome (SJS) is a potentially life-threatening mucocutaneous eruption clinically characterized by a diffuse distribution of targetoid lesions or purpuric macules.1 Histologically, epidermal necrosis with a subepidermal split and variable inflammation is seen.2 SJS affects females twice as often as males and can occur in both children and adults.1,3,4 The etiology most commonly relates to medications, particularly anticonvulsants, sulfonamides, penicillins, allopurinol, nonsteroidal anti-inflammatory drugs (NSAIDs),5-13 and, rarely, cephalosporin and ciprofloxacin.14-15 We describe a case of SJS associated with doxycycline. This is the second case of doxycycline-associated SJS reported in the English language literature.16

Case Report
A 46-year-old man presented with a blistering eruption of 4 days’ duration. Two weeks prior to the eruption, doxycycline hyclate 100 mg twice daily had been started for a dental infection. He took no other medications and had not taken doxycycline in the past. Four days prior to presentation, a pruritic tender eruption developed on his central chest and back, quickly progressing to affect most of his body, including his palms, soles, and oral mucosa. He described his discomfort as “lying in the sand with a bad sunburn.” A drug reaction was suspected; doxycycline was discontinued the day after the eruption began, and his primary care physician prescribed prednison e 60 mg daily 3 days prior to presentation to us. His past medical history was remarkable only for occasional oral aphthous ulcers, most recently 1 to 2 weeks prior to this eruption. He reported arthralgia and decreased oral intake secondary to tender oral lesions. He denied fever, chills, or night sweats.

Physical examination revealed a well-nourished uncomfortable man. Widespread (>50% body surface area [BSA]) 1- to 3-cm, erythematous, dusky macules and atypical targetoid macules were present on the trunk (Figure 1), extremities, face, palms, and soles, with confluence on the central trunk. Many of the targetoid lesions were centrally vesicular, purpuric, and superficially eroded, though sheets of...

Figure 1. A 46-year-old man with Stevens-Johnson syndrome showing generalized erythema with edematous targetoid macules and formation of vesiculobullae on the trunk.

Accepted for publication February 17, 2006.
From the Department of Dermatology, University of Iowa, Iowa City. The authors report no conflict of interest.
Reprints: Hobart W. Walling, MD, PhD, Dermatology PC, 6000 University Ave, Suite 450, West Des Moines, IA 50266 (e-mail: hobart-walling@uiowa.edu).
epidermal necrosis were absent. Nikolsky sign was present, and skin detachment was estimated at 7% BSA. There were a few bullae and erosions of the buccal and labial mucosa, as well as soft and hard palate (Figure 2), with conjunctival erythema. There were a few erythematous macules on the base of the penis and scrotum, but urethral or perianal erythema was not present. A punch biopsy from the periphery of a typical vesicular lesion on the back showed interface dermatitis with full-thickness epidermal necrosis, and a mild superficial perivascular and interstitial inflammatory infiltrate, consistent with SJS (Figures 3 and 4). Direct immunofluorescence was negative. Laboratory investigations within reference range included liver function tests, complete blood count, electrolytes, blood urea nitrogen, creatinine, and chest radiography. Culture and direct fluorescent antibody testing for herpes simplex virus of oral lesions was negative.

The patient was hospitalized and prescribed hydroxyzine hydrochloride 25 mg twice daily, mupirocin ointment for eroded areas, and continued prednisone, tapered to 40 mg once daily. During hospitalization, the patient was febrile to 39.2°C, with blood and urine cultures negative for bacteria. At the time of discharge 5 days later, he was afebrile with an elevated white blood cell count attributed to the corticosteroid. The patient was much improved at the 2-week follow-up with fading of the eruption to postinflammatory hyperpigmentation. He remains free of recurrence one year later.

Comment
SJS is part of a continuum that includes erythema multiforme (EM) and toxic epidermal necrolysis (TEN). All 3 are characterized clinically by targetoid lesions and histologically by interface dermatitis and satellite necrosis of keratinocytes. EM is a self-limited disorder that arises from a hypersensitivity response to certain infections (most commonly herpes simplex virus). Lesions are diffuse, and frequently there is symmetrical extremity and facial involvement. In contrast, the majority of SJS and TEN disorders are caused by drug reactions; lesions predominate the trunk, involve more than one mucosal site, and may show Nikolsky sign. TEN is the most severe manifestation of this spectrum, with diffuse involvement, necrosis, and sloughing over 10% BSA and a significant risk of mortality. Mortality of SJS and TEN is predictable by the severity-of-illness score for TEN (SCORTEN), using clinical and laboratory parameters (ie, age; heart rate; presence of malignancy; BSA involved; abnormalities in serum urea, bicarbonate, and glucose). In this case, the 7-point SCORTEN analysis of these clinical parameters predicted a good prognosis with mortality risk of 12%.

SJS was first described in 1922, and in 1950 it was proposed that EM be termed EM minor and SJS be termed EM major to reflect their similar pathologic process but differing severity. EM major and SJS are now understood as distinct presentations. Morphologically, EM consists of typical or raised atypical targets on the extremities and face, while SJS consists of widespread purpuric macules or flat atypical targets favoring the trunk; in contrast to TEN, both have detachment at less than 10% BSA. Cote et al discussed the different histologic patterns between these entities, with EM major showing an interface dermatitis with lichenoid inflammation and SJS showing a predominantly necrotic pattern.
Stevens-Johnson Syndrome

with major epidermal necrosis and minimal inflammatory infiltration. Recurrence of SJS is uncommon, but rechallenge in medication-induced cases results in more severe disease with shorter latency. HLA-A29, B12, B*1502, and DR7 haplotypes have been associated with SJS.1,23

Many drugs have been associated with SJS, especially anticonvulsants, sulfonamides, penicillins, allopurinol, and NSAIDs, and less commonly cephalosporin, tetracycline, quinolones, and imidazole antifungals.5-13 Aside from drugs, physical factors such as UV light, x-ray exposure, and immune dysregulation may play a role.1 The mechanism behind SJS lies in the cell-mediated cytotoxic immune reaction that destroys keratinocytes expressing foreign or drug-related antigens.1,24

Treatment of SJS includes hospitalization for supportive care. Systemic corticosteroids may be beneficial though controversial.3 Recently, there has been great interest in the potential for treating SJS and TEN with intravenous immunoglobulin (IVIG), which inhibits apoptosis via an anti-Fas activity.25 Studies of IVIG for SJS have reached conflicting conclusions. A retrospective study of 12 patients with SJS showed benefit of high-dose IVIG in blocking the progression of SJS and reducing the time to complete skin healing.26 However, a prospective noncomparative study of 34 patients with SJS or TEN found no benefit of IVIG in reducing mortality.25 In the present case, IVIG therapy was considered but was opted against as the patient’s condition was responding to the corticosteroids that had been started locally. Early withdrawal of the offending medication was likely critical in his favorable course.27

Our patient represents a rare case of doxycycline-induced SJS. In our literature review, there was only one other reported case in the English language literature.16 Another case has been reported in the French literature.28 Awareness is essential of this rare but potentially life-threatening reaction to a medication commonly used in dermatology.

REFERENCES
Stevens-Johnson Syndrome


